NanoInterventions

NanoInterventions was a medical technology company and joint venture focused on accelerating the development of cardiovascular therapies through advanced preclinical models. The company's primary innovation was a proprietary "mouse stent model" that utilized genetically modified mice with human-like atherosclerosis to test the efficacy of new stent coatings and drug-eluting systems. This platform enabled rapid screening of interventional cardiology products, modeling human vascular responses to injury at a fraction of the time and cost of traditional large-animal studies. NanoInterventions offered a range of services including custom nanoparticle coating via the ElectroNanospray process, stent design, and GLP-compliant preclinical analytical services. The company was formed through a strategic partnership between Nanocopoeia, The Integra Group, and Stentome LLC.